Financial Contrast: Advanced Biomed (ADVB) vs. Its Rivals

Advanced Biomed (NASDAQ:ADVB – Get Free Report) is one of 959 public companies in the “Software” industry, but how does it contrast to its peers? We will compare Advanced Biomed to similar businesses based on the strength of its risk, institutional ownership, earnings, analyst recommendations, valuation, profitability and dividends.

Risk and Volatility

Advanced Biomed has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, Advanced Biomed’s peers have a beta of 1.35, suggesting that their average stock price is 35% more volatile than the S&P 500.

Profitability

This table compares Advanced Biomed and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Advanced Biomed N/A -67.24% -59.01%
Advanced Biomed Competitors -581.39% 26.52% -9.00%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Advanced Biomed and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Advanced Biomed 1 0 0 0 1.00
Advanced Biomed Competitors 5868 21647 45058 1506 2.57

As a group, “Software” companies have a potential upside of 32.93%. Given Advanced Biomed’s peers stronger consensus rating and higher possible upside, analysts plainly believe Advanced Biomed has less favorable growth aspects than its peers.

Valuation and Earnings

This table compares Advanced Biomed and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Advanced Biomed $130,000.00 $6.68 million 0.37
Advanced Biomed Competitors $1.78 billion $382.69 million 111.15

Advanced Biomed’s peers have higher revenue and earnings than Advanced Biomed. Advanced Biomed is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

41.6% of shares of all “Software” companies are owned by institutional investors. 27.0% of Advanced Biomed shares are owned by insiders. Comparatively, 19.8% of shares of all “Software” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Advanced Biomed peers beat Advanced Biomed on 11 of the 13 factors compared.

About Advanced Biomed

(Get Free Report)

Advanced Biomed Inc. is a medical technology company focused on cell-based diagnostic and therapeutic applications. Its work centers on technologies for isolating and analyzing cells for use in medical and life-sciences settings. The company’s activities include developing systems intended to support cancer diagnostics and cell-processing applications. These technologies are aimed at helping researchers and healthcare organizations work with cells for diagnostic or therapeutic purposes. Publicly available information about Advanced Biomed’s product portfolio, commercial reach and leadership is limited, so specific products and operating geographies are not described here.

Receive News & Ratings for Advanced Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Biomed and related companies with MarketBeat.com's FREE daily email newsletter.